Kineta Research and Development Expenses 2014-2024 | KANT
Kineta research and development expenses from 2014 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.
Kineta Annual Research and Development Expenses (Millions of US $) |
2023 |
$9 |
2022 |
$16 |
2021 |
$16 |
2020 |
$22 |
2019 |
$23 |
2018 |
$50 |
2017 |
$54 |
2016 |
$34 |
2015 |
$23 |
2014 |
$17 |
2013 |
$13 |
Kineta Quarterly Research and Development Expenses (Millions of US $) |
2024-06-30 |
$1 |
2024-03-31 |
$3 |
2023-12-31 |
$2 |
2023-09-30 |
$2 |
2023-06-30 |
$3 |
2023-03-31 |
$3 |
2022-12-31 |
$5 |
2022-09-30 |
$3 |
2022-06-30 |
$4 |
2022-03-31 |
$4 |
2021-12-31 |
$-5 |
2021-09-30 |
$7 |
2021-06-30 |
$7 |
2021-03-31 |
$7 |
2020-12-31 |
$8 |
2020-09-30 |
$5 |
2020-06-30 |
$4 |
2020-03-31 |
$5 |
2019-12-31 |
$-20 |
2019-09-30 |
$10 |
2019-06-30 |
$17 |
2019-03-31 |
$16 |
2018-12-31 |
$14 |
2018-09-30 |
$16 |
2018-06-30 |
$13 |
2018-03-31 |
$8 |
2017-12-31 |
$12 |
2017-09-30 |
$13 |
2017-06-30 |
$15 |
2017-03-31 |
$13 |
2016-12-31 |
$10 |
2016-09-30 |
$9 |
2016-06-30 |
$7 |
2016-03-31 |
$7 |
2015-12-31 |
$6 |
2015-09-30 |
$6 |
2015-06-30 |
$6 |
2015-03-31 |
$5 |
2014-12-31 |
|
2013-12-31 |
|
Sector |
Industry |
Market Cap |
Revenue |
Medical |
MED-BIOMED/GENE |
$0.000B |
$0.005B |
Kineta, Inc. is a clinical-stage biotechnology company. It develops next-generation immunotherapies that address the major challenges with current cancer therapy. The company's lead asset is KVA12123, a novel VISTA blocking immunotherapy. Kineta merged with Yumanity Therapeutics, Inc., and is based in Seattle.
|